Royal Bank of Canada Cuts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $33.00

Karyopharm Therapeutics (NASDAQ:KPTI) had its target price reduced by stock analysts at Royal Bank of Canada from $34.00 to $33.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock.

Several other brokerages have also issued reports on KPTI. Robert W. Baird decreased their target price on Karyopharm Therapeutics from $54.00 to $42.00 and set an “outperform” rating for the company in a research report on Tuesday. HC Wainwright increased their price target on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. Finally, Barclays increased their price target on Karyopharm Therapeutics from $5.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.20.

Karyopharm Therapeutics Price Performance

Shares of Karyopharm Therapeutics stock opened at $4.85 on Tuesday. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $17.85. The firm has a market cap of $41.56 million, a PE ratio of -4.75 and a beta of 0.33. The stock has a fifty day moving average price of $5.46 and a 200-day moving average price of $8.84.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Monday, May 12th. The company reported ($2.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.21) by $1.44. The business had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $35.12 million. As a group, equities analysts anticipate that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in KPTI. Geode Capital Management LLC boosted its stake in Karyopharm Therapeutics by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock worth $942,000 after purchasing an additional 36,922 shares during the period. Marshall Wace LLP boosted its stake in Karyopharm Therapeutics by 15.3% in the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock worth $1,633,000 after purchasing an additional 319,187 shares during the period. TD Waterhouse Canada Inc. bought a new position in Karyopharm Therapeutics in the 4th quarter worth about $32,000. Silverarc Capital Management LLC boosted its stake in Karyopharm Therapeutics by 6.7% in the 4th quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock worth $403,000 after purchasing an additional 37,524 shares during the period. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Karyopharm Therapeutics by 46.3% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock worth $4,274,000 after purchasing an additional 2,000,000 shares during the period. Institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).